Györffy and colleagues correlated Herceptin resistant tumours from patients with DUSPs involved in development of Herceptin resistance in HER2 positive breast cancer, and suggested that DUSP4 is involved in this process [40]. The gene discussed is DUSP4; the disease is breast carcinoma.